The effect of topical ketanserin on intraocular pressure (IOP) in normotensive and hypertensive eyes was evaluated. The study was performed on 10 healthy volunteers and 10 glaucomatous patients. Systolic arterial blood pressure (SBP), diastolic arterial blood pressure (DBP), heart rate (HR), IOP, tonographic outflow facility, pupil diameter, corneal thickness, and tear secretion were recorded at baseline and at 1 hour intervals for 12 hours after topical administration of 0-5% ketanserin or placebo, given in a randomised, double masked, crossover fashion. The alternative treatment was given 1 week later. In ali subjects ketanserin significantly lowered IOP, while no variations in SBP, DBP, HR, pupil diameter, corneal thickness, and tear secretion were found. When subjects received placebo no significant variations of lOP occurred. Total outflow facility, measured by conventional tonography, increased significantly after drug administration in all subjects. Ketanserin is effective up to 6 hours in control subjects and 9 hours in glaucomatous patients. The placebo did not induce any change in this component of the aqueous humour dynamic in normal or in glaucomatous eyes. The findings indicate that topical ketanserin might be added to the list of antiglaucomatous agents. (BrJ Ophthalmol 1993; 77: 344-348) Eye Clinic,
Ketanserin is an antihypertensive agent with predominantly serotonergic blocking properties and additional mild postsympatholytic action.' 2 Comparative trials have indicated that ketanserin is as effective as 1B blockers or diuretics in reducing blood pressure in patients suffering from arterial hypertension. 34 Recently, we reported that orally administered ketanserin also significantly reduced intraocular pressure (IOP) both in healthy volunteers5'6 and in glaucomatous patients7 by increasing the total outflow facility, measured by conventional tonography, and thus by reducing the outflow resistance. When topically applied, ketanserin lowers IOP in rabbits, cats, and monkeys.8-'0 To date, no studies on the effect of topical ketanserin in humans have been reported.
The aim of this clinical trial was to verify whether ketanserin administered topically was able to reduce IOP in normal and glaucomatous eyes. Preliminary results have been reported elsewhere.
Patients and methods This study included 10 glaucomatous patients (five men and five women, age range 40-50 years)
with IOP values greater than or equal to 22 mm Hg in each eye. All patients had visual field glaucomatous defects (nasal step, paracentral defects, temporal wedge, arcuate defect, and generalised depression of light sensitivity)'2 and were being treated with 13 Figure 2 shows the changes in IOP after ketanserin and/or placebo administration in normal and glaucomatous eyes. In both groups ketanserin was able to reduce IOP significantly after hour. At the subsequent measure- Time (hours) ments the degree of reduction was even more evident (normotensive eyes, from baseline: after 1 hour -12-5%, after 2 hours -13-1%, after 3 hours -13-5%, after 4 hours -13'7%, after 5 hours -14-1%; hypertensive eyes from baseline: after 1 hour -16%, after 2 hours -20%, after 3 hours -25%, after 4 hours -25d1%, and remained statistically different for up to S hours in control subjects and 9 hours in glaucomatous patients. In both groups the peaks were reached Time (hours), Table 2 . While placebo did not affect this parameter, 1 hour after ketanserin administration there was a significant increase of the tonographic outflow facility value in glaucomatous patients (+24-8%, p<0 05). At the subsequent measurements the increase in total outflow facility was even greater (+40% after 2 hours, p<0-01; +43% after 3 hours, p<0-01); normotensive eyes also showed a significant increase in total outflow facility. The levels obtained slowly decreased to insignificant values Table 2 Tonographic outflow variations facility after ketanserin andlorplacebo administration in 10 control subjects and in 10 glaucomatous patients Student's t test was used for statistical analysis (*) p<005;
(t) P<0 I1. after 6 hours in control subjects and 9 hours in glaucomatous patients. In both groups the peaks were reached after 3-4 hours. As can be seen from Table 3 there were no significant variations in pupil diameter after administration of either ketanserin or placebo to both groups.
The Schirmer and break up time tests did not show any significant difference in either group when patients were receiving the drug or when placebo was administered. No significant variations of the corneal thickness were noted. Finally, there were no adverse effects after the application of either ketanserin or placebo (that is, conjunctival hyperaemia, aqueous humour flare, anterior chamber cellular response, etc).
Discussion
Our results show that topical administration of ketanserin significantly reduces IOP in normotensive and hypertensive human eyes. Moreover, the magnitude of IOP reduction was greater than that observed using the oral route5-7 and was consistent with previous experimental studies in animals"'0 and with our preliminary findings in humans."
The mechanism by which ketanserin decreases IOP in humans could be explained on the basis of the increase in total outflow facility, as demonstrated by the conventional tonography. Ketanserin administration does not induce significant variations of tear secretion and does not alter the stability of the lacrimal film. Rather, it is not unrealistic to hypothesise that ketanserin is able to improve tear secretion and to preserve the stability of the lacrimal film directly, because of the lack of effects on 1 agonist receptors29 and indirectly, by improving the blood flow to the lacrimal gland.30 In this sense, the compound does not exhibit the well known ocular side effects induced by,3 blockers3' -that is, dry eye and superficial keratitis, which frequently occur in patients undergoing treatment.
Topical administration of ketanserin did not result in significant variations of SBP, DBP, and HR. D Blockers, the most effective drugs at present in the treatment and management of glaucoma, are reported to have systemic cardiovascular and pulmonary side effects -that is, decreased cardiac rate and myocardial contractility, prolongation of atrioventricular conduction, reduction of blood pressure, 32-35 and bronchoconstriction.36 37 On the contrary, ketanserin seems to be particularly suited for the treatment of patients with congestive heart failure and other low output shock conditions; it restores depressed cardiac function and reduces cardiac oxygen consumption,2938 without effects on atrioventricular conduction. Moreover, it does not influence symptoms and indices of airway resistance in patients with asthma because it has no detrimental effects on the bronchial tree.39
The lack of all these side effects together with its efficacy in lowering IOP puts ketanserin in a more favourable position when compared with 13 blocking agents in the treatment of glaucoma. Moreover, the analysis of the response curves suggests that two or three daily applications will manage IOP in glaucomatous patients. Further studies based on long term follow up are needed to verify the real effectiveness of this novel antiglaucomatous drug. 
